arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Fortress Biotech, Inc.

FBIO
$1.82 ▼ -0.15 (-7.38%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Fortress Biotech, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $50.8M
Dividend Yield —
Revenue Growth 9.7% ↗
Op. Margin -111.0% ↗
ROIC -67.4% ↗
FCF / Share $-2.36 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield —
Debt / Equity 1.05
info Valuation on last close. End-of-day price, Nov 5, 2026.

21-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$63.26M
↑ +9.7% —
Net Income Profit after all expenses
$6.82M
↑ +114.8% —
Operating Margin Operating profit as % of sales
-111.0%
↑ +42.0% 2th
FCF / Share Free cash flow per share
$-2.36
↑ +38.9% —
Long-Term Debt Long-term obligations
$52.42M
↓ -9.6% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
24
Returns
78
Financial Health ↑
31
Cash Quality
2

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 21 years · 75 quarters